Anita J. Chawla
Education
Ph.D., economics, University of Michigan; B.A., economics and political science, Wellesley College
Summary of Experience
Dr. Chawla has more than 25 years of experience as an economist in the health care sector. Since joining Analysis Group in 2007, she has helped global biopharmaceutical, diagnostic, and medical device manufacturers - as well as development-stage companies - address product development and commercialization objectives, particularly as they relate to market access. Her work has spanned a wide range of therapeutic areas, including multiple indications in oncology. Her recent client work includes landscape assessments, economic modeling, and strategic plans to inform evidence generation in the context of product development and market access launch strategy; forecasts to help prioritize research and support licensing and venture funding discussions; payer research and advisory boards; and launch materials that communicate a product's clinical and economic value to support evidence-based reviews. Dr. Chawla recently led an engagement comprising a fully integrated market access strategy and related tactics to support the launch of a novel drug to treat an orphan disease.
Dr. Chawla's recent publications include an assessment of the impact of regulatory requirements for cardiovascular risk evaluation for diabetes therapies. She has served as a reviewer or referee for several journals, including Value in Health, Health Affairs, Health Services Research, Journal of the American Medical Association, and Journal of Business and Economic Statistics. Prior to joining Analysis Group, she was head of the health economics and outcomes research department at Genentech, Inc., where she also supported the oncology franchise.
-
Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma
PLOS One, 2022
2022Harvey MJ, Zhong Y, Morris E, Beverage JN, Epstein RS, Chawla AJ
-
Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis
Journal of Managed Care & Specialty Pharmacy, 2021
2021Croteau SE, Cook K, Sheikh L, Chawla A, Sammon J, Solari P, Kim B, Hinds D, Thornburg CD
-
Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer
JCO Precision Oncology, 2021
2021Harvey MJ, Cunningham R, Sawchyn B, Montesion M, Reddy P, McBride A, Chawla AJ
-
Healthcare resource utilization and costs associated with postpartum depression among commercially insured households
Current Medical Research and Opinion, 2020
2020Epperson CN, Huang M, Cook K, Gupta D, Chawla A, Greenberg PE, Eldar-Lissai A
-
Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A
Journal of Medical Economics, 2020
2020Cook K, Forbes SP, Adamski K, Ma JJ, Chawla A, Garrison Jr LP
-
Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer
Journal of Medical Economics. 2019 Feb;22(2):140-150
2019Signorovitch J, Zhou Z, Ryan J, Anhorn R, Chawla A
-
The humanistic burden of postpartum depression: a systematic literature review
Current Medical Research and Opinion. 2019 Mar;35(3):383-393
2019Moore Simas TA, Huang MY, Patton C, Reinhart M, Chawla AJ, Clemson C, Eldar-Lissai A
-
Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers
Journal of Medical Economics. 2018 Jun;21(6):543-552
2018Chawla A, Peeples M, Li N, Anhorn R, Ryan J, Signorovitch J
-
Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study
JCO Precision Oncology, November 2, 2018
2018Chawla A; Janku F; Wheler J; Miller V; Ryan J; Anhorn, R; Zhou Z; Signorovitch J
-
A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population
Infectious Diseases and Therapy. 2018 Jun;7(2):183-195
2018Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, Steinhart C
-
Utility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling
Expert Review of Pharmacoeconomics & Outcomes Research. Apr 2017;17(2):153-164
2017Brown J, Cook K, Adamski K, Lau J, Bargo D, Breen S, Chawla A
-
Following Recent Trends In Affordable Care Act Insurance
Law360, September 9, 2016
2016Chawla A, Cook K
-
An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Prac
Clinical Lymphoma Myeloma and Leukemia, 2016 08. e-pub ahead of print 2016/10/01
2016Ma E, Bonthapally V, Chawla A, Lefebvre P, Swords R, Lafeuille MH, Fortier J, Emond B, Duh MS, Dezube BJ.
-
Estimating the Incremental Net Health Benefit of Requirements for Cardiovascular Risk Evaluation for Diabetes Therapies
Pharmacoepidemiology and Drug Safety, January 2014
2014Chawla A, Mytelka D, McBride S, Nellesen D, Elkins B, Ball D, Kalsekar A, Towse A, Garrison L
-
A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation
Journal of Managed Care Pharmacy, November-December 2013, Vol. 19, No. 9
2013Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT
-
Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation
Postgraduate Medicine, March 2013, Vol. 125, No. 2
2013Nellesen D, Chawla A, Oh DL, Weissman T, Lavins BJ, Murray CW
-
Personalized Medicine: Trends in Clinical Studies Based on National Registry Data
ISPOR Poster, 2009
2009Nellesen D, Person A, Yee K, Chawla A